Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises BofA Merrill Lynch on TomoTherapy’s Sale to Accuray

March 7, 2011

NEW YORK, March 7, 2011 — Covington & Burling LLP represented BofA Merrill Lynch, financial adviser to TomoTherapy Incorporated, in its sale to Accuray Incorporated for $277 million.

Under terms of the agreement, TomoTherapy will be sold to Accuray for $4.80 per share in cash and Accuray stock.

TomoTherapy is a creator of advanced radiation therapy solutions for cancer care. Accuray is a global leader in the field of radiosurgery.

The New York-based Covington corporate team was led by partner Jack Bodner and Richard Kruger, an associate at the firm.

Share this article: